The efficacy of lisdexamfetamine dimesylate (LDX) in children (aged 6–12 years) with attention-deficit/hyperactivity disorder (ADHD) who had received methylphenidate (MPH) within the 6 months prior to study enrollment was examined in post hoc analyses of two studies.

- Study 1: 7-week, open-label design
- Study 2: randomized, double-blind, placebo-controlled, crossover, laboratory school design

Improvements in symptoms compared with baseline (study 1) and placebo (study 2) were similar in patients who had received previous MPH treatment to those seen in the overall study populations.

These results suggest that LDX is an effective treatment option for children with ADHD who were previously treated with MPH.